Seagen Aims To Make Tukysa First Drug For HER2-Positive Colorectal Cancer
The Phase II MOUNTAINEER trial showed a benefit for patients with HER2-positive metastatic colorectal cancer treated with the tyrosine kinase inhibitor in combination with trastuzumab.
You may also be interested in...
Keeping Track: New Claims For Tukysa, Brukinsa; US FDA Wants More Patients To Support Donanemab, Pediatric Airsupra Bids
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Seagen Taps Epstein As New CEO After A Tumultuous Year
Former Novartis executive and venture capitalist David Epstein will step in to lead Seagen after its founder resigned in a scandal and amid M&A speculation.
Merck & Co Closing In On Seagen Acquisition
Merck is closing in on the acquisition of the antibody drug conjugate specialists which would help the pharma giant consolidate its presence in oncology.